Suthep Namwongsamran, GM of M&H Manufacturing, provides insights into the distinctive model that has allowed M&H to become one of Thailand’s leading domestic pharmaceutical manufacturers. He also outlines the expected development of the M&H’s international strategy and his focus on bringing biosimilars to Thailand via mutually beneficial partnerships.
We need many more medicines to be available in the country to be able to support elderly people
Nico Form-Zuellig, general manager of Interthai Pharmaceutical Manufacturing, shares his thoughts on the Thai pharmaceutical market as a newcomer to the country and goes on to elaborate on the company’s…
Philippe Pedeboscq, managing director of Siemens Healthineers, shares his impressions after taking the lead of the company’s Thailand affiliate two years ago. Pedeboscq goes on to explain his strategic mission…
Shinsuke Yuasa, president of Thai Otsuka discusses the importance of Thailand for Otsuka as its first overseas market back in 1973. Yuasa goes on to highlight how the affiliate is…
Writing in the September edition of DIA’s Global Forum magazine, Rosilawati Ahmad of Malaysia’s National Pharmaceutical Regulatory Agency; Tharnkamol Chanprapaph of the Thai FDA; and Samvel Azatyan, Valerio Reggi, and…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
The latest from Southeast Asian pharma, including soaring output in Singapore, tax breaks for research in Indonesia, Thai firm Factorytalk’s UK expansion, and the potential for a Russian COVID-19 vaccine…
See our Cookie Privacy Policy Here